Wednesday, the FDA granted accelerated approval to Bristol Myers Squibb Co’s (NYSE:BMY) Breyanzi (lisocabtagene maraleucel; ...

The FDA has broadened the use of Bristol Myers Squibb’s CAR-T therapy Breyanzi to another type of blood cancer. | The FDA has ...

The U.S. health regulator on Wednesday approved the expanded use of Bristol Myers Squibb's cancer cell therapy Breyanzi for ...

FDA has given accelerated approval for lisocabtagene maraleucel (liso-cel; Breyanzi) for patients with relapsed or refractory ...

Lisocabtagene maraleucel was approved by the FDA to treat adults with relapsed/refractory follicular lymphoma who were ...

The approval is based on results from the open-label, global, multicentre, single-arm Phase II TRANSCEND FL clinical trial.

The accelerated approval comes a few weeks after Breyanzi (lisocabtagene maraleucel or liso-cel) became the first CAR-T to be ...

By Colin Kellaher Bristol Myers Squibb has won U.S. Food and Drug Administration expanded approval of its CAR-T cell therapy Breyanzi for adults ...

The agency approved the autologous CAR T-cell therapy after around 96 percent of patients in the Phase II TRANSCEND-FL trial responded to it.

This is the second accelerated approval the FDA has granted to Bristol Myers Squibb’s chimeric antigen receptor T-cell ...

Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval ...

Isabel elaborated on her experience in a lengthy caption, admitting her initial disregard for an early cancer symptom — a ...